Breye Therapeutics raised €67.5 million (about $75.6 million) in a Series A to advance oral danegaptide for non-proliferative diabetic retinopathy (NPDR) into later-stage clinical development. The company plans to start a Phase II program in NPDR with clinical proof-of-concept, targeting vascular leakage and capillary breakdown pathways tied to Cx43 stabilization and VEGF signaling modulation.